Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-coding RNA for adipogenesis and lipogenesis (linc-ADAL)
- Target
- linc-ADAL
- Molecular classification
- Long non-coding RNA (lncRNA), RNA regulatory molecule (not a protein, enzyme, or receptor)
01
Overview
Long intergenic non-coding RNA for adipogenesis and lipogenesis (linc-ADAL) is a non-coding RNA molecule, located between the AQPEP and AP3S1 genes on human chromosome 5. It is highly enriched in adipose tissue and plays a pivotal role in regulating the differentiation of preadipocytes into mature adipocytes and in promoting lipid accumulation. Mechanistically, linc-ADAL directly interacts with hnRNPU (a nuclear protein) and IGF2BP2 (a cytoplasmic mRNA-binding protein) at different subcellular sites to coordinate gene expression programs necessary for adipogenesis and lipogenesis. Knockdown studies show that loss of linc-ADAL impairs both adipocyte maturation and expression of key genes involved in lipid synthesis. It is under study as a key factor associated with obesity and metabolic diseases, but is not itself currently a drug target
- Other names
- linc-ADALlincRNA for adipogenesis and lipogenesisLINC-ADALLINCADL
02
Mechanism of action
Not applicable; linc-ADAL is not targeted by drugs, but acts by regulating gene expression through interaction with nuclear (hnRNPU) and cytoplasmic (IGF2BP2) proteins involved in adipocyte differentiation and lipid metabolism
03
Biological functions
Adipocyte differentiation (adipogenesis)Lipogenesis regulation (fatty acid synthesis in adipose tissue)Interacts with proteins such as hnRNPU and IGF2BP2 to control gene expression in fat cells
04
Disease associations
ObesityMetabolic disorders (through its impact on fat tissue development and lipid storage)
05
Safety considerations
None reported. No safety or toxicity issues are attributed to linc-ADAL itself, as it is an endogenous regulatory RNA and not a therapeutic target or drug.
06
Biomarkers
Expression of linc-ADAL is a marker for mature adipocytes and is highly enriched in human adipose tissue. Its expression correlates with adipose tissue status and may be explored as a biomarker in studies of obesity and fat metabolism.
Beyond the preview
Go deeper on Long intergenic non-coding RNA for adipogenesis and lipogenesis (linc-ADAL).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-coding RNA for adipogenesis and lipogenesis (linc-ADAL).